Issue link: https://optometricmanagementsupplements.epubxp.com/i/571093
S E P T E M B E R 2 0 1 5 • O P T O M E T R I C M A N A G E M E N T . C O M S 7 Similarly, HyperGel™, the unique material in our Biotrue® ONEday daily disposable contact lenses, was designed for patients who spend many hours per day staring at screens. Biotrue® ONEday was designed to behave like the eye itself, mimicking the eye's natural lipid layer and staying hydrated for up to 16 hours. 1 Biotrue® ONEday daily disposable contact lenses for Presbyopia combine the multifocal optics of the 3-zone progressive design with the comfort of our HyperGel™ material. Patients can now see clearly and comfortably with contacts, close up, far away, and every- where in between. 1 PeroxiClear® 3% hydrogen peroxide cleaning & disinfecting solution incor- porates Triple-Moist Technology®— three moisturizing agents working in concert to attract, spread, and retain moisture. Te surfactant in PeroxiClear® stays on contact lenses for 20 hours of wear compared to the leading peroxide brand, which loses almost all surfactant afer just one hour of wear. 1 PeroxiClear® also provides exceptional disinfection in just 4 hours, so users can reinsert their lenses sooner. 1 Biotrue® Multipurpose Solution (MPS) was developed specifcally to address optometrists' need for a dual action disinfecting system along with additional lubricants to keep contact lenses comfortable for longer. Biotrue® MPS was formulated to work like the eyes with bio-inspired in- novations — pH equal to healthy tears, keeps healthy tear proteins active, maintaining their inherent antimicrobial activity, and utilizes hyaluronan, the eye's natural lubricant to deliver long lasting hydration. 1 We are particularly ap- preciative of optometry's support of Biotrue® MPS. EXCITING PIPELINE Over the next year, optometrists will see further expan- sion of these new contact lens platforms, with toric and multifocal options to allow optometrists to ofer these great technologies to more patients. We have a rich pipeline of innovative contact lenses and lens care solutions that we plan to bring to market over the next 24 months. Tese ad- vances are the fruit of Bausch + Lomb's investment in re- search and innovation to advance the science of sight. With the support of Valeant Pharmaceuticals, we are expanding our manufacturing facilities for contact lenses in Roches- ter, NY and in Waterford, Ireland. At Bausch + Lomb and Valeant, we are fervent in our support of discovery research. Where we may difer from other eye care companies is where we believe that research should occur. We believe that the greatest innovation oc- curs in doctors' ofces, academic centers, and at startup companies, where brilliant scientists and clinicians can fol- low their passions. It is then the role of industry to develop these ideas into commercial products, take them through the regulatory process and bring them to clinicians for the beneft of patients. We pledge to listen to eye care practitioners, work with them to improve patient care, and invest in new technolo- gies to provide the industry-leading portfolio of vision care products. Bausch + Lomb has supported optometry since we introduced the frst sof contact lens in 1971. With one of our industry's leading portfolio of products, our dedi- cated and knowledgeable sales and clinical professionals, and our most robust pipeline ever, our goal remains to be Optometry's preferred partner in eye health ®/ ™ are trademarks of Bausch & Lomb Incorporated or its af fliates. US/ ZUS/15/0200 © Bausch & Lomb Incorporated. Serving the optometric community with a full eye health portfolio S P O N S O R E D B Y B A U S C H + L O M B OPTOME TRIC MANAGEMENT CORPORATE PROFILE 1 Data on fle at Bausch + Lomb